AGTR1 and hydrops fetalis: Sacubitril/valsartan (SAC/VAL) combines an angiotensin II type 1 receptor (AT1R) blocker and a neprilysin inhibitor, ARNi, was approved by the U.S. Food and Drug Administration for heart failure (HF) with reduced ejection fraction treatment in 201513.